Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

RAPT Therapeutics stock

RAPT
US75382E1091
A2PNYQ

Price

2.01
Today +/-
+0.04
Today %
+2.52 %
P

RAPT Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the RAPT Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the RAPT Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the RAPT Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze RAPT Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

RAPT Therapeutics Stock Price History

DateRAPT Therapeutics Price
9/30/20242.01 undefined
9/27/20241.96 undefined
9/26/20241.87 undefined
9/25/20241.76 undefined
9/24/20241.76 undefined
9/23/20241.76 undefined
9/20/20241.79 undefined
9/19/20241.93 undefined
9/18/20241.82 undefined
9/17/20241.90 undefined
9/16/20241.88 undefined
9/13/20241.95 undefined
9/12/20241.93 undefined
9/11/20241.93 undefined
9/10/20241.99 undefined
9/9/20242.01 undefined
9/6/20241.83 undefined
9/5/20241.93 undefined
9/4/20242.04 undefined
9/3/20242.02 undefined

RAPT Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into RAPT Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by RAPT Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects RAPT Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of RAPT Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into RAPT Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing RAPT Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on RAPT Therapeutics’s growth potential.

RAPT Therapeutics Revenue, EBIT and net profit per share

DateRAPT Therapeutics RevenueRAPT Therapeutics EBITRAPT Therapeutics Net Income
2029e303.01 M undefined0 undefined27.77 M undefined
2028e155.58 M undefined-358.02 M undefined-76.71 M undefined
2027e88.23 M undefined-302.94 M undefined-132.78 M undefined
2026e12.57 M undefined-149.6 M undefined-88.82 M undefined
2025e0 undefined-115.08 M undefined-67.91 M undefined
2024e0 undefined-113.22 M undefined-89.57 M undefined
20230 undefined-127.06 M undefined-116.8 M undefined
20221.53 M undefined-85.8 M undefined-83.84 M undefined
20213.81 M undefined-69.21 M undefined-69.2 M undefined
20205.04 M undefined-53.21 M undefined-52.89 M undefined
20190 undefined-43.63 M undefined-43 M undefined
20180 undefined-36.95 M undefined-36.15 M undefined
20170 undefined-29.33 M undefined-29.12 M undefined

RAPT Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
0005310001288155303
-----40.00-66.67----633.3376.1495.48
-------------
0000000000000
-29-36-43-53-69-85-127-113-115-149-302-3580
----1,060.00-2,300.00-8,500.00----1,241.67-343.18-230.97-
-29-36-43-52-69-83-116-89-67-88-132-7627
-24.1419.4420.9332.6920.2939.76-23.28-24.7231.3450.00-42.42-135.53
22.7522.7522.7524.1327.3932.5438.34000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The RAPT Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the RAPT Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2017201820192020202120222023
             
47.563.877.4111.5189.7249.1158.86
0000000
0000000
0000000
0.71.33.14.13.33.62.92
48.265.180.5115.6193252.7161.78
1.94.23.732.79.57.68
0000000
0000000
0000000
0000000
0.20.40.40.42.943.87
2.14.64.13.45.613.511.55
50.369.784.6119198.6266.2173.33
             
108.6161.100000
2122.4235319.2470.6613.1631.61
-82.8-119-162-214.8-284-367.9-484.68
-600-6000-200-2000103
0000000
46.263.973104.2186.4245.2147.04
1.11.81.12.423.45.18
1.52.53.64.96.310.816.55
0.70.44.54.41.300.11
0000000
0000000
3.34.79.211.79.614.221.84
0000000
0000000
0.912.232.76.84.46
0.912.232.76.84.46
4.25.711.414.712.32126.29
50.469.684.4118.9198.7266.2173.33
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of RAPT Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand RAPT Therapeutics's financial health and stability.

Assets

RAPT Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that RAPT Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of RAPT Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into RAPT Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-29-36-43-52-69-83-116
1,0001,0001,0001,0001,0001,0001,000
0000000
0042-4-15
12417212430
0000000
0000000
-27-32-35-40-61-70-97
-1-30000-1
-1-30-87-81-45104
000-87-80-44105
0000000
0000000
305249751411311
305249751411311
-------
0000000
11613-520148
-28.24-36.45-36.36-40.89-61.79-71.62-98.17
0000000

RAPT Therapeutics stock margins

The RAPT Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of RAPT Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for RAPT Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the RAPT Therapeutics's sales revenue. A higher gross margin percentage indicates that the RAPT Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the RAPT Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the RAPT Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the RAPT Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the RAPT Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the RAPT Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

RAPT Therapeutics Margin History

RAPT Therapeutics Gross marginRAPT Therapeutics Profit marginRAPT Therapeutics EBIT marginRAPT Therapeutics Profit margin
2029e0 %0 %9.16 %
2028e0 %-230.12 %-49.31 %
2027e0 %-343.35 %-150.49 %
2026e0 %-1,189.92 %-706.47 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %-5,607.84 %-5,479.74 %
20210 %-1,816.54 %-1,816.27 %
20200 %-1,055.75 %-1,049.4 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

RAPT Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The RAPT Therapeutics earnings per share therefore indicates how much revenue RAPT Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue RAPT Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates RAPT Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of RAPT Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating RAPT Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

RAPT Therapeutics Revenue, EBIT and net profit per share

DateRAPT Therapeutics Sales per ShareRAPT Therapeutics EBIT per shareRAPT Therapeutics Earnings per Share
2029e8.68 undefined0 undefined0.8 undefined
2028e4.46 undefined0 undefined-2.2 undefined
2027e2.53 undefined0 undefined-3.8 undefined
2026e0.36 undefined0 undefined-2.54 undefined
2025e0 undefined0 undefined-1.95 undefined
2024e0 undefined0 undefined-2.57 undefined
20230 undefined-3.31 undefined-3.05 undefined
20220.05 undefined-2.64 undefined-2.58 undefined
20210.14 undefined-2.53 undefined-2.53 undefined
20200.21 undefined-2.21 undefined-2.19 undefined
20190 undefined-1.92 undefined-1.89 undefined
20180 undefined-1.62 undefined-1.59 undefined
20170 undefined-1.29 undefined-1.28 undefined

RAPT Therapeutics business model

Rapt Therapeutics Inc. is an emerging pharmaceutical company that was originally founded in 2015 under the name "FLX Bio". The company is based in San Francisco, California. Rapt is the name of the biological process that the company uses to identify and develop drug candidates. Rapt Therapeutics specializes in developing innovative immunotherapies for cancer treatment. The goal is to harness the power of the immune system to support the body in fighting cancer. The company focuses on developing prophylactic cancer vaccines and immunotherapies that aim to directly combat cancer cells and strengthen the body's defenses. The company's business model is based on an innovative technology platform that is able to identify antibodies and other molecules that activate the RAPT process, which is important for combating cancer cells. With this technology, Rapt Therapeutics can quickly and accurately identify potential drug candidates that are suitable for the development of cancer immunotherapies. At the time of its founding, Rapt primarily focused on developing immunotherapeutics for solid tumors, a type of cancer that originates in a specific tissue in the body and does not spread to adjacent tissues or organs. However, the company has since expanded its portfolio to include the development of therapeutics for hematological cancers such as leukemia and lymphoma. Rapt Therapeutics employs a pipeline-based research strategy. The pipeline-based research strategy means that Rapt Therapeutics develops a variety of drug candidates targeting different disease indications. The drug candidates are then tested in different phases of clinical development to evaluate their efficacy and safety. To date, Rapt Therapeutics has four drug candidates in clinical development. The first candidate, RPT193, is currently being tested in phase 1 clinical trials for the treatment of various solid tumors. The second candidate, RPT835, is currently in preclinical development and targets the treatment of leukemia. The third candidate, FLX475, is also in preclinical development and targets the treatment of multiple sclerosis. The fourth candidate, FLX475, is currently in phase 1 clinical trials and targets the treatment of certain solid tumors. In addition, Rapt Therapeutics has also entered into a number of partnerships with other pharmaceutical companies. In 2018, Rapt Therapeutics signed a strategic collaboration with AstraZeneca to accelerate the development of RPT193. Under this collaboration, AstraZeneca will test RPT193 in clinical trials. In 2019, Rapt Therapeutics entered into a research and development collaboration with Hanmi Pharmaceutical Co. Ltd. to accelerate the discovery, development, and commercialization of drug candidates for cancer and other diseases. Rapt Therapeutics is pursuing a long-term strategy to become a leading company in immunotherapy development. By continuing its research and development of cancer immunotherapies, Rapt has the potential to improve the lives of millions of people suffering from cancer and other serious diseases. RAPT Therapeutics is one of the most popular companies on Eulerpool.com.

RAPT Therapeutics SWOT Analysis

Strengths

Rapt Therapeutics Inc has several strengths that contribute to its success in the market. One of its key strengths is its strong research and development capabilities. The company invests heavily in developing innovative therapeutics, which gives it a competitive edge.

Another strength is the company's strong intellectual property portfolio. Rapt Therapeutics holds numerous patents, which provide it with protection and exclusivity for its products, making it difficult for competitors to replicate its offerings.

Weaknesses

Despite its strengths, Rapt Therapeutics Inc also faces certain weaknesses. One weakness is its heavy reliance on a limited number of product lines. This concentration increases the company's vulnerability to market fluctuations and regulatory challenges.

Another weakness is the company's relatively small scale of operations compared to some of its larger competitors. This may limit its ability to negotiate favorable terms with suppliers or reach a wider customer base.

Opportunities

There are several opportunities for Rapt Therapeutics Inc to capitalize on. One such opportunity lies in the growing demand for innovative therapeutics in the market. The company can leverage its strong R&D capabilities to develop new products that cater to unmet medical needs, thereby capturing a larger market share.

Another opportunity is the potential for strategic partnerships and collaborations. By joining forces with other pharmaceutical companies or research institutions, Rapt Therapeutics can gain access to additional resources, knowledge, and expertise, accelerating its growth and expanding its product pipeline.

Threats

Rapt Therapeutics Inc faces certain threats that could impact its performance. One major threat is intense competition within the pharmaceutical industry. The presence of established players and constant developments by competitors can pose challenges to the company's market share and profitability.

Additionally, regulatory changes and strict compliance requirements pose a threat to the company's operations. Any changes in regulations governing drug development, approval processes, or pricing could significantly impact Rapt Therapeutics' ability to bring products to market in a timely and cost-effective manner.

RAPT Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

RAPT Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

RAPT Therapeutics shares outstanding

The number of shares was RAPT Therapeutics in 2023 — This indicates how many shares 38.338 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue RAPT Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates RAPT Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of RAPT Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating RAPT Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for RAPT Therapeutics.

RAPT Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.73 -0.71  (3.32 %)2024 Q2
3/31/2024-0.82 -0.79  (4.17 %)2024 Q1
12/31/2023-0.88 -0.8  (8.68 %)2023 Q4
9/30/2023-0.77 -0.82  (-6.73 %)2023 Q3
6/30/2023-0.8 -0.66  (17.22 %)2023 Q2
3/31/2023-0.69 -0.76  (-9.57 %)2023 Q1
12/31/2022-0.67 -0.64  (4.06 %)2022 Q4
9/30/2022-0.68 -0.63  (7.81 %)2022 Q3
6/30/2022-0.77 -0.62  (18.95 %)2022 Q2
3/31/2022-0.69 -0.69  (0.33 %)2022 Q1
1
2

Eulerpool ESG Scorecard© for the RAPT Therapeutics stock

Eulerpool World ESG Rating (EESG©)

51/ 100

🌱 Environment

54

👫 Social

63

🏛️ Governance

37

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

RAPT Therapeutics shareholders

%
Name
Stocks
Change
Date
9.58063 % T. Rowe Price Associates, Inc.3,343,641-129,20612/31/2023
7.68086 % The Column Group LP2,680,621012/31/2023
6.37135 % BlackRock Institutional Trust Company, N.A.2,223,601125,65412/31/2023
6.13166 % Perceptive Advisors LLC2,139,950219,29212/31/2023
5.87529 % The Vanguard Group, Inc.2,050,47632,91612/31/2023
5.14030 % Deep Track Capital LP1,793,966-197,43712/31/2023
4.16778 % State Street Global Advisors (US)1,454,55648,05412/31/2023
3.66149 % T. Rowe Price Investment Management, Inc.1,277,86125,96912/31/2023
3.15115 % Great Point Partners, LLC1,099,753-358,31712/31/2023
2.76742 % Kingdon Capital Management, L.L.C.965,828160,00012/31/2023
1
2
3
4
5
...
10

RAPT Therapeutics Executives and Management Board

Dr. Brian Wong51
RAPT Therapeutics President, Chief Executive Officer, Director (since 2019)
Compensation 5.21 M
Mr. Rodney Young60
RAPT Therapeutics Chief Financial Officer
Compensation 1.54 M
Dr. Dirk Brockstedt54
RAPT Therapeutics Chief Scientific Officer
Compensation 1.48 M
Dr. William Ho57
RAPT Therapeutics Chief Medical Officer
Compensation 1.4 M
Mr. William Rieflin63
RAPT Therapeutics Independent Chairman of the Board
Compensation 175,464
1
2
3

RAPT Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Merck & Co Stock
Merck & Co
SupplierCustomer-0,24-0,05-0,71-0,63-0,53-0,06
1

Most common questions regarding RAPT Therapeutics

What values and corporate philosophy does RAPT Therapeutics represent?

Rapt Therapeutics Inc is committed to delivering innovative solutions in the field of oncology. Their corporate philosophy revolves around advancing the understanding of the immune system and developing targeted therapies to improve patient outcomes. Rapt Therapeutics Inc values scientific excellence, collaboration, and a patient-centric approach. With a focus on precision medicine, they aim to harness the potential of immunology to treat cancers effectively. Through their dedication to research and development, Rapt Therapeutics Inc strives to make a difference in the lives of cancer patients by providing transformative treatment options.

In which countries and regions is RAPT Therapeutics primarily present?

Rapt Therapeutics Inc is primarily present in the United States.

What significant milestones has the company RAPT Therapeutics achieved?

Some significant milestones achieved by Rapt Therapeutics Inc include the completion of successful clinical trials for their lead drug candidate, FLX475, which has shown promising results in the treatment of multiple cancers. Additionally, Rapt Therapeutics Inc received the Orphan Drug Designation from the FDA for FLX475, highlighting the drug's potential in addressing rare diseases. The company has also established strategic collaborations with renowned research institutions and pharmaceutical companies to further advance their pipeline of innovative therapeutics. These achievements demonstrate Rapt Therapeutics Inc's dedication to developing novel treatments and their commitment to improving patients' lives.

What is the history and background of the company RAPT Therapeutics?

Rapt Therapeutics Inc is a biopharmaceutical company based in the United States. The company focuses on developing therapies to modulate the immune system and target critical immune checkpoints for the treatment of cancer. Rapt Therapeutics Inc was founded in 2015 and has since been dedicated to advancing their innovative drug pipeline. With a mission to improve the lives of patients, Rapt Therapeutics Inc combines cutting-edge research and scientific expertise to develop novel treatment options for a range of cancers.

Who are the main competitors of RAPT Therapeutics in the market?

The main competitors of Rapt Therapeutics Inc in the market include companies such as Merck & Co., Inc., Bristol-Myers Squibb Company, and Genentech, Inc. These companies operate in the pharmaceutical industry and are engaged in developing and marketing therapies and treatments for various diseases and medical conditions. Rapt Therapeutics Inc faces competition in terms of research and development, as well as commercialization of innovative therapies.

In which industries is RAPT Therapeutics primarily active?

Rapt Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of RAPT Therapeutics?

The business model of Rapt Therapeutics Inc. focuses on developing and commercializing transformative small molecule drugs for patients with unmet medical needs. The company focuses on the discovery and development of oral small molecule therapies that target critical signaling pathways involved in various diseases. Rapt Therapeutics Inc. aims to leverage its expertise in immunology and oncology to identify and develop potential therapeutic candidates. Through rigorous research and development, the company aims to bring innovative drugs to the market, ultimately improving patient outcomes and addressing significant unmet medical needs.

What is the P/E ratio of RAPT Therapeutics 2024?

The RAPT Therapeutics P/E ratio is -0.86.

What is the P/S ratio of RAPT Therapeutics 2024?

The RAPT Therapeutics P/S ratio is 0.

What is the AlleAktien quality score of RAPT Therapeutics?

The AlleAktien quality score for RAPT Therapeutics is 2/10.

What is the revenue of RAPT Therapeutics 2024?

The revenue cannot currently be calculated for RAPT Therapeutics.

How high is the profit of RAPT Therapeutics 2024?

The expected RAPT Therapeutics profit is -89.57 M USD.

What is the business model of RAPT Therapeutics

Rapt Therapeutics Inc is a biopharmaceutical company based in San Francisco, California, focused on the development and commercialization of therapeutics for the treatment of cancer and inflammatory diseases. The company was founded in 2015. Rapt Therapeutics' business model is based on an innovative platform for identifying target molecules and researching and developing small molecules for the targeted treatment of cancer and inflammation. The company utilizes the body's own immune cells to fight tumors. Rapt Therapeutics has developed several products in recent years, including FLX475 for the treatment of cancer and inflammatory diseases. FLX475 is an orally administered drug that inhibits the activation of T cells, resulting in an anti-inflammatory effect. Rapt Therapeutics currently has four cancer drugs in the pipeline, including IL-4Ra antagonists for the treatment of nervous system cancer. Another aspect of the company's business is collaboration with other biopharmaceutical companies to develop innovative therapeutics based on the Rapt platform technology. Rapt Therapeutics works with leading companies in the industry such as Merck, Pfizer, and Genentech. The Rapt platform technology is unique and facilitates the search for suitable target molecules and potential drugs. A key part of Rapt Therapeutics' business model is also collaboration with scientific partners, primarily academic research institutions. The research and development of innovative cancer therapies requires close collaboration between the industry and the academic research community. Rapt Therapeutics specializes in collaborating with leading academic institutions to accelerate research in innovative ways. To ensure that the company can always offer its customers the latest research findings and technologies, Rapt Therapeutics also invests in research and development in other areas such as genomics, biology, and immunology. In summary, Rapt Therapeutics' business model is to develop and strategically use innovative chemicals to effectively treat cancer and inflammatory diseases. The company's platform technology allows for fast and targeted search for the best target molecules and potential drugs. Collaboration with other companies and academic institutions plays an important role in accelerating research findings in innovative ways.

What is the RAPT Therapeutics dividend?

RAPT Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does RAPT Therapeutics pay dividends?

The dividend cannot currently be calculated for RAPT Therapeutics or the company does not pay out a dividend.

What is the RAPT Therapeutics ISIN?

The ISIN of RAPT Therapeutics is US75382E1091.

What is the RAPT Therapeutics WKN?

The WKN of RAPT Therapeutics is A2PNYQ.

What is the RAPT Therapeutics ticker?

The ticker of RAPT Therapeutics is RAPT.

How much dividend does RAPT Therapeutics pay?

Over the past 12 months, RAPT Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RAPT Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of RAPT Therapeutics?

The current dividend yield of RAPT Therapeutics is .

When does RAPT Therapeutics pay dividends?

RAPT Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of RAPT Therapeutics?

RAPT Therapeutics paid dividends every year for the past 0 years.

What is the dividend of RAPT Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is RAPT Therapeutics located?

RAPT Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von RAPT Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of RAPT Therapeutics from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did RAPT Therapeutics pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of RAPT Therapeutics in the year 2023?

In the year 2023, RAPT Therapeutics distributed 0 USD as dividends.

In which currency does RAPT Therapeutics pay out the dividend?

The dividends of RAPT Therapeutics are distributed in USD.

All fundamentals about RAPT Therapeutics

Our stock analysis for RAPT Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RAPT Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.